What should you know about metastatic hormone-sensitive prostate cancer?

Metastatic means cancer cells have travelled to sites outside the prostate, such as lymph nodes or bones. Hormone-sensitive means the cancer is currently affected by reducing androgen signals, particularly testosterone. Your team may use scans, blood tests and tissue information to understand where the cancer is and how it is behaving.

Symptoms vary. Difficulty passing urine can occur with prostate problems, but the symptom alone does not establish cancer or tell you whether cancer has spread. Bone involvement may cause persistent pain or weakness, so mention new symptoms even when they seem unrelated.

Treatment commonly combines hormone-directed treatment with another cancer treatment chosen according to the spread, biopsy findings, previous care, general health and personal priorities. Options discussed may include systemic treatment, radiotherapy, or selected procedures. Radiotherapy can target painful or threatening areas, while bone-strengthening therapy may be considered when bone health is at risk.

Ask how each option is intended to control cancer, which side effects need early attention, and how treatment response will be monitored. A plan can be adjusted when scans, symptoms or blood results change.

Contact your oncology team promptly for new or worsening back pain, leg weakness, numbness, loss of bladder or bowel control, inability to pass urine, fever during treatment, or pain that is not controlled. These symptoms can require urgent assessment, particularly when cancer may affect bones or the nerves near the spine.

Which sites are involved, and what did the scans show? Why is this cancer considered hormone-sensitive? What treatment combination do you recommend first? How will you check response? Should I discuss radiotherapy, targeted radioisotope therapy, brachytherapy, bone-strengthening therapy, prostate removal surgery or robotic cancer surgery in my situation?